Bespoke Extracts (BSPK) Liabilities and Shareholders Equity (2011 - 2025)
Bespoke Extracts (BSPK) reported Liabilities and Shareholders Equity of $295573.0 for Q3 2025, down 12.56% on a YoY basis from $338015.0 in Q3 2024, and up 10.69% sequentially from $267038.0 in Q2 2025.
Bespoke Extracts (BSPK) Liabilities and Shareholders Equity (2011 - 2025) Analysis & Trends
Bespoke Extracts (BSPK) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $295573.0 in Q3 2025.
- For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 12.56% year-over-year to $295573.0; the trailing twelve-month figure through Sep 2025 stood at $1.2 million (down 17.37% YoY), and the FY2024 full-year result was $359088.0, up 1.33% from the prior year.
- Liabilities and Shareholders Equity grew to $295573.0 in Q3 2025, from $267038.0 in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $646520.0 in Q1 2021 to a low of $67106.0 in Q4 2021.
- A 5-year average of $354638.1 and a median of $359088.0 in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Peak annual rise in Liabilities and Shareholders Equity reached 530.08% in 2021, while the deepest fall reached 79.98% in 2021.
- Tracing BSPK's Liabilities and Shareholders Equity over 5 years: stood at $67106.0 in 2021, then soared by 510.36% to $409591.0 in 2022, then decreased by 13.48% to $354360.0 in 2023, then increased by 1.33% to $359088.0 in 2024, then decreased by 17.69% to $295573.0 in 2025.
- Business Quant data shows BSPK's Liabilities and Shareholders Equity at $295573.0 in Q3 2025, $267038.0 in Q2 2025, and $248125.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.71 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 69.30 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Bespoke Extracts | 1.12 Mn | 1.11 Mn | 234,175.00 | 295,573.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 295,573.00 |
| Jun 30, 2025 | 267,038.00 |
| Mar 31, 2025 | 248,125.00 |
| Dec 31, 2024 | 359,088.00 |
| Sep 30, 2024 | 338,015.00 |
| Jun 30, 2024 | 367,477.00 |
| Mar 31, 2024 | 355,836.00 |
| Dec 31, 2023 | 354,360.00 |
| Sep 30, 2023 | 388,109.00 |
| Jun 30, 2023 | 448,286.00 |
| Mar 31, 2023 | 478,509.00 |
| Dec 31, 2022 | 409,591.00 |
| Sep 30, 2022 | 369,636.00 |
| Jun 30, 2022 | 404,628.00 |
| Mar 31, 2022 | 522,550.00 |
| Nov 30, 2021 | 67,106.00 |
| Aug 31, 2021 | 124,520.00 |
| May 31, 2021 | 293,157.00 |
| Feb 28, 2021 | 646,520.00 |
| Nov 30, 2020 | 335,247.00 |